Forty‐three key gene expressions involved in the effect of indoleamine 2,3‐dioxygenase 1 expression on cancer prognosis may be a potential indoleamine 2,3‐dioxygenase 1 inhibitor biomarker
Open Access
- 17 February 2021
- journal article
- letter
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (2), e330
- https://doi.org/10.1002/ctm2.330
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current DevelopmentCurrent Oncology Reports, 2019
- The modulatory properties of Si Jun Zi Tang enhancing anticancer of gefitinib by an integrating approachBiomedicine & Pharmacotherapy, 2019
- The Immune Landscape of CancerImmunity, 2018
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome AnalyticsCell, 2018
- The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessibleNucleic Acids Research, 2016
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- WGCNA: an R package for weighted correlation network analysisBMC Bioinformatics, 2008
- Use of within-array replicate spots for assessing differential expression in microarray experimentsBioinformatics, 2005
- Methods for categorizing a prognostic variable in a multivariable settingStatistics in Medicine, 2003